PMC:7381711 / 1355-1529
Annnotations
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T8","span":{"begin":42,"end":49},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma82839"}],"text":"ants in critical illness, plausibility of heparin for COVID-19 is sufficiently robust to justify urgent randomized controlled trials to determine the safety and effectiveness"}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"32","span":{"begin":42,"end":49},"obj":"Chemical"},{"id":"42","span":{"begin":8,"end":24},"obj":"Disease"},{"id":"43","span":{"begin":54,"end":62},"obj":"Disease"}],"attributes":[{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"MESH:D006493"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:D016638"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ants in critical illness, plausibility of heparin for COVID-19 is sufficiently robust to justify urgent randomized controlled trials to determine the safety and effectiveness"}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T17","span":{"begin":54,"end":62},"obj":"Disease"}],"attributes":[{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"ants in critical illness, plausibility of heparin for COVID-19 is sufficiently robust to justify urgent randomized controlled trials to determine the safety and effectiveness"}
LitCovid-PD-CHEBI
{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T11","span":{"begin":42,"end":49},"obj":"Chemical"}],"attributes":[{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"}],"text":"ants in critical illness, plausibility of heparin for COVID-19 is sufficiently robust to justify urgent randomized controlled trials to determine the safety and effectiveness"}